Evidence map›Paper›PMID 38957465›Full record

ArticleFrontiers in immunology2024

Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: an explorative study.

Sarah Louise Murphy, Nora Reka Balzer, Trine Ranheim, Ellen Lund Sagen, Camilla Huse, Vigdis Bjerkeli, Annika E Michelsen, Ane-Kristine Finbråten, Lars Heggelund, Anne Ma Dyrhol-Riise and 9 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sarah Louise MurphyResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Nora Reka BalzerGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Trine RanheimResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Ellen Lund SagenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Camilla HuseResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Vigdis BjerkeliResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Annika E MichelsenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Ane-Kristine FinbråtenDepartment of Internal Medicine, Lovisenberg Diakonal Hospital, Oslo, Norway.
Lars HeggelundDepartment of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Anne Ma Dyrhol-RiiseInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Anders TveitaDepartment of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.
Aleksander Rygh HoltenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Marius TrøseidResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Thomas UlasGenomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Andreas Barratt-DueDivision of Laboratory Medicine, Department of Immunology, Oslo University Hospital, Oslo, Norway.
Bente HalvorsenResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Tuva Børresdatter DahlResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a reciprocal relationship between extracellular matrix (ECM) remodelling and inflammation that could be operating in the progression of severe COVID-19. To explore the immune-driven ECM remodelling in COVID-19, we in this explorative study analysed these interactions in hospitalised COVID-19 patients. RNA sequencing and flow analysis were performed on peripheral blood mononuclear cells. Inflammatory mediators in plasma were measured by ELISA and MSD, and clinical information from hospitalised COVID-19 patients (N=15) at admission was included in the analysis. Further, we reanalysed two publicly available datasets: (1) lung tissue RNA-sequencing dataset (N=5) and (2) proteomics dataset from PBCM. ECM remodelling pathways were enriched in PBMC from COVID-19 patients compared to healthy controls. Patients treated at the intensive care unit (ICU) expressed distinct ECM remodelling gene profiles compared to patients in the hospital ward. Several markers were strongly correlated to immune cell subsets, and the dysregulation in the ICU patients was positively associated with plasma levels of inflammatory cytokines and negatively associated with B-cell activating factors. Finally, our analysis of publicly accessible datasets revealed (i) an augmented ECM remodelling signature in inflamed lung tissue compared to non-inflamed tissue and (ii) proteomics analysis of PBMC from severe COVID-19 patients demonstrated an up-regulation in an ECM remodelling pathway. Our results may suggest the presence of an interaction between ECM remodelling, inflammation, and immune cells, potentially initiating or perpetuating pulmonary pathology in severe COVID-19.

Indexed as

COVID-19Extracellular MatrixLeukocytes, MononuclearSARS-CoV-2AdultAgedCytokinesFemaleHumansLungMaleMiddle AgedProteomicsCytokinesCOVID-19extracellular matriximmune responselung pathologySARS-CoV-2

Identifiers

PMID38957465
PMCPMC11217192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.